CoChat

Cerebral Creatine Deficiencies: A Group of Treatable Intellectual Developmental Disorders

van Karnebeek, Clara, Stockler-Ipsiroglu, Sylvia · 2014 · Seminars in Neurology

The DOI matches its Crossref record.

Abstract

Currently there are 91 treatable inborn errors of metabolism that cause intellectual developmental disorders. Cerebral creatine deficiencies (CDD) comprise three of these: arginine: glycine amidinotransferase [AGAT], guanidinoacetate methyltransferase [GAMT], and X-linked creatine transporter deficiency [SLC6A8]. Intellectual developmental disorder and cerebral creatine deficiency are the hallmarks of CDD. Additional clinical features include prominent speech delay, autism, epilepsy, extrapyramidal movement disorders, and signal changes in the globus pallidus. Patients with GAMT deficiency exhibit the most severe clinical spectrum. Myopathy is a distinct feature in AGAT deficiency. Guanidinoacetate (GAA) is the immediate product in the creatine biosynthetic pathway. Low GAA concentrations in urine, plasma, and cerebrospinal fluid are characteristic diagnostic markers for AGAT deficiency, while high GAA concentrations are characteristic markers for GAMT deficiency. An elevated ratio of urinary creatine /creatinine excretion serves as a diagnostic marker in males with SLC6A8 deficiency. Treatment strategies include oral supplementation of high-dose creatine-monohydrate for all three CDD. Guanidinoacetate-reducing strategies (high-dose ornithine, arginine-restricted diet) are additionally employed in GAMT deficiency. Supplementation of substrates for intracerebral creatine synthesis (arginine, glycine) has been used additionally to treat SLC6A8 deficiency. Early recognition and treatment improves outcomes. Normal outcomes in neonatally ascertained siblings from index families with AGAT and GAMT deficiency suggest a potential benefit of newborn screening for these disorders.

Overview

Integrity signals

Registry

Crossref · 10.1055/s-0034-1386772

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Still being checked.

Cited by

See all 72

Metadata

Authors
van Karnebeek, C., & Stockler-Ipsiroglu, S.
Affiliations
Division of Biochemical Diseases, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, Canada
Venue
Seminars in Neurology
Published
2014-09-05
Volume
34
Issue
03
Pages
350-356
ISSN
  • 0271-8235 (ISSN-L)
  • 1098-9021
OpenAlex
W2027428988
Cited by
72
References
0
Citations by year
2026: 4 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 7 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 6 · 2017: 6 · 2016: 6 · 2014: 1
FWCI
2.98
Type
journal article
Language
en
Open access
closed
Locations
  • Seminars in Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
intellectual disability, guanidinoacetate methyltransferase deficiency, SLC6A8, guanidinoacetic acid, creatine synthesis, creatine supplementation, myopathy, speech delay, autism spectrum disorder, epilepsy, globus pallidus, newborn screening, inborn errors of metabolism
MeSH terms
Amidinotransferases, Creatine, Humans, Language Development Disorders, Intellectual Disability, Movement Disorders, Brain Diseases, Metabolic, Inborn, X-Linked Intellectual Disability, Plasma Membrane Neurotransmitter Transport Proteins, Guanidinoacetate N-Methyltransferase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cerebral Creatine Deficiencies: A Group of Treatable Intellectual Developmental Disorders. https://app.cochat.ai/papers/10.1055/s-0034-1386772
The paper
van Karnebeek, C., & Stockler-Ipsiroglu, S. (2014). Cerebral Creatine Deficiencies: A Group of Treatable Intellectual Developmental Disorders. Seminars in Neurology. https://doi.org/10.1055/s-0034-1386772

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.